Jaguar Health, Inc. Q3 FY2024 earnings call

Key Points

• Lisa Conte introduced Jaguar Health, mentioning Q3 2024 revenue of $3.1M, up from prior quarters.
• Launched FDA-approved oral mucositis prescription product Gelclair in the US, focusing on supportive care for cancer patients.
• Discussed OnTarget trial results, with abstracts accepted for San Antonio Breast Cancer Symposium, showing meaningful clinical signals in breast and lung cancer.
• Pravin Chaturvedi discussed regulatory and development plans for crofelemer in cancer therapy-related diarrhea and rare diseases (MVID, SBS-IF), including Phase II trials in Q4 2024.
• Carol Lizak provided financial highlights, noting loss from operations decreased from $8.8M in Q3 2023 to $7.3M in Q3 2024.
• Mentioned the Make Cancer Less Shitty campaign with patient ambassadors to address cancer-related side effects.

Net third quarter 2024 revenue was approximately $3.1 million, which increased approximately 14% versus the second quarter of 2024 ($2.7 million revenue) and approximately 11% versus Q3 2023 ($2.8 million revenue). No specific breakdown of product segments beyond overall revenue figures.

Forward-Looking Statements

• Near-term catalysts in Q4 2024 and early 2025 include Phase II trials for MVID and SBS-IF, presentations at San Antonio Breast Cancer Symposium, and continued commercial launch of Gelclair.
• Plan to submit breast cancer subgroup responder analysis to peer-reviewed journal and request FDA meeting in H1 2025 to discuss regulatory pathways for crofelemer in breast cancer patients.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, as outlined in the company's Form 10-K and other SEC filings. General risks include uncertainties regarding market acceptance, competitive products, regulatory requirements, and clinical trial outcomes.

Q: Are we looking to partner with the right company to enhance the pipeline? Are you looking into institutional investors?

A: Absolutely looking into institutional investors due to liquidity in JAGX stock. Also, have global unencumbered rights to crofelemer with existing partnerships, and balance partnering for non-dilutive dollars vs. long-term commercial impact.

Q: Can you explain the extension data from the 12 weeks in the OnTarget trial?

A: Focused on first 12-week responder analysis for San Antonio submission. Data from Stage 2 (12-week extension) will be evaluated, with analysis expected in mid to late 2025.

Q: Question about achieving profitability in the biotech sector in development-stage pharmaceutical companies.

A: Crofelemer (HIV indication) is a positive contributor. Gelclair's commercialization plan aims for positive contribution soon. Focus on late-stage clinical development with risk reduction to target blockbuster opportunities.

Q: Can discussions with FDA be fast-tracked?

A: Short answer is no. FDA follows first-in, first-out, and depends on unmet need and impact factor. They expedite where necessary but take a thorough approach.